Introduction
============

The immune system influences the fate of developing cancers by functioning not only as a tumor promoter that facilitates cellular transformation, promotes tumor growth, and sculpts tumor cell immunogenicity [@B1]-[@B6], but also as an extrinsic tumor suppressor that either destroys developing tumors or restrains their expansion [@B2], [@B5], [@B7]. Programmed death-ligand 1 (PD-L1), which is expressed on many cancer and immune cells, plays an important role in blocking the cancer immunity cycle by binding programmed death-1 (PD-1) and B7.1, both of which are negative regulators of T lymphocyte activation [@B8]. Indeed, tumor cells from different locations express PD-L1 and thus can inhibit the immune response. Recently, clinical trials testing anti-PD-L1 or anti-PD1 agents for restoration of antitumor immunity have reported very promising outcomes, notably in melanoma and renal, lung, prostate, and bladder cancer. PD-L1 expression has been studied in different cancers including kidney, lung, pancreas, esophagus, ovary, colorectal, head and neck, breast, and skin (melanoma), with evidence of correlations with clinicopathological tumor features in several studies [@B9]-[@B15]. Neuroendocrine tumors (NET) are a heterogeneous group of malignancies derived from neuroendocrine cell compartments with roles in both the endocrine and the nervous system. The majority of NETs are gastroenteropancreatic (GEP) in origin, arising in the foregut, midgut, or hindgut [@B16]. Although NETs are known to be very rare [@B17], recent studies based on the Surveillance, Epidemiology and End Results (SEER) cancer registry and European studies demonstrated an increasing incidence of NETs [@B17]. Moreover, a Korean study showed a remarkable increase in the incidence of GEP-NETs during the last decade [@B18]. Although GEP-NETs are increasingly being diagnosed, a concomitant improvement in outcomes has not been noted. Recently, two molecularly targeted agents, sunitinib and everolimus, have been approved for advanced pancreatic NETs [@B19], [@B20] and might prolong the survival of patients with GEP-NET. However, most GEP-NET patients experience resistance to these treatments and additional effective treatment options are very limited [@B21]. Cancer immunotherapy is presently one of the areas in which major medical breakthroughs are being witnessed with impressive results reported by several groups [@B8], [@B22]. One key target of cancer immunotherapies is the PD1-PD-L1 pathway; however, this pathway has not been studied in metastatic GEP-NETs. Here, we investigated the impact of PD-L1 expression on survival in 32 patients with metastatic GEP-NET and searched for correlations between PD-L1 expression and clinicopathlogic data.

Material and methods
====================

Patients
--------

Among patients who were pathologically diagnosed with metastatic GEP-NETs in Samsung Medical Center between June 2011 and September 2014, 32 were analyzed for PD-L1 expression in this study. The following clinicopathological characteristics were collected for all 32 patients: age, gender, primary site, tumor grade according to the 2010 WHO classification, liver metastasis, number of metastatic sites, site of metastasis, and information on chemotherapy.

Immunohistochemistry (IHC) of PD-L1
-----------------------------------

Tumor sections were freshly cut to 4 mm and dried at 60℃ for 30 minute. PDL-1 immunohistochemistry (rabbit anti-human PDL-1 monoclonal, 1:25, clone SP142; Ventana, Tuscon, AZ) was performed on an automated immunostainer (Benchmark; Ventana). Antigen retrieval was performed for 92 min with CC1 and the antibody was incubated for 120 min un 37℃ in Ventana BencaMark XT. Signal visualization was achieved with the Optiview DAB IHC detection kit (Catalogue number 760-700) and Optiview Amplification kit (Catalogue number 860-099).

PD-L1 expression was evaluated on tumor cells. Tumor infiltrating immune cells are not identified in all cases. The proportion of PD-L1-positive cells was estimated as the percentage of total tumor cells; tumor cells typically showed membranous staining with a variably component of cytoplasmic staining. Specimens were categorized as IHC negative or positive if \< 1% or ≥ 1% of cells were stained by PD-L1 mAb, respectively (Figure [1](#F1){ref-type="fig"}).

Statistical analyses
--------------------

Correlation between the status of PD-L1 expression and clinicopathological variables was analyzed using the t-test or the Fisher\'s exact test as appropriate or one-way analysis of variance. Treatment outcomes were estimated as response rate (RR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). PFS and OS were defined as the time from the first study treatment to the date of disease progression or death, respectively. Descriptive statistics were reported as proportions and medians. Kaplan-Meier estimates were used in the analysis of all time to event variables, and the 95% confidence interval (CI) for the median time to event was computed.

Results
=======

Patient characteristics
-----------------------

Among patients who were pathologically diagnosed with metastatic GEP-NET in Samsung Medical Center between June 2011 and September 2014, 32 were analyzed for PD-L1 expression in this study. Baseline characteristics of these 32 patients are listed in Table [1](#T1){ref-type="table"}. The median age of the patients was 60.0 years (range, 35-88) and the male to female ratio was 1.29. Primary sites included 24 foregut-derived GEP-NETs \[stomach (n=1), duodenum (n=2), biliary tract (n=7), and pancreas (n=14)\] and 8 hindgut-derived GEP-NETs of distal colon and rectum. According to WHO classification, 17 patients had grade 3 neuroendocrine carcinoma (NEC) and 15 had grade 2 NET. All 32 patients had liver metastases. Twenty-one patients (65.6%) had 2 or more metastatic sites. The majority (78.1%) of patients received the recommended systemic treatment after the diagnosis of metastatic GEP-NETs. However, 7 patients (21.9%) were managed by only best supportive care because of patient preference or poor performance status (PS).

The correlation between PD-L1 expression and clinicopathological variables
--------------------------------------------------------------------------

Among the 32 patients with metastatic GEP-NET analyzed for PD-L1 expression, 7 (21.9%) exhibited expression of PD-L1 in tumor tissues. The expression of PD-L1 was significantly associated with high-grade WHO classification (grade 3) (p=0.008) but not with gender, primary site, or number of metastatic sites (p\>0.05) (Table [2](#T2){ref-type="table"}). Among 21 patients receiving the recommended systemic therapies as first line, 4 patients had PD-L1-positive tumors and 17 patients had PD-L1-negative tumors. There was significant difference in the tumor response according to the status of PD-L1 (Table [3](#T3){ref-type="table"}).

The impact of PD-L1 on patient survival
---------------------------------------

In 21 patients receiving systemic therapies as first line, the median progression-free survival (PFS) was 4.9 months (95% CI 4.2-5.5). There was a significant difference in PFS between patients who were positive and negative for PD-L1 (4.2 vs. 5.1 months, p=0.047) (Figure [2](#F2){ref-type="fig"}). The median overall survival (OS) was 17.3 months (95% CI 11.7-22.8) for all 32 patients. According to the status of PD-L1, median OS was 16.0 months (95% CI 7.7-24.1) in patients with PD-L1-positive tumors and 24.8 months (95% CI 2.6-46.9) in those with PD-L1-negative tumors (p=0.037) (Figure [3](#F3){ref-type="fig"}).

Discussion
==========

Inhibition of PD-L1 is a promising novel target in cancer immunotherapy [@B23]. This study analyzed a heterogeneous collection of metastatic GEP-NETs for expression of PD-L1. We aimed to investigate the role of PD-L1 expression as a predictive and prognostic marker for survival in 32 patients with metastatic GEP-NET. We also searched for correlations between PD-L1 expression and clinicopathlogic data. This analysis revealed that the expression of PD-L1 was significantly associated with high-grade WHO classification (grade 3) (p=0.008) but not with gender, primary site, and the number of metastatic sites (p\>0.050). Moreover, PD-L1 might be a useful predictive and prognostic biomarker for survival in metastatic GEP-NETs. To our knowledge, this is the first report evaluating the characteristics and value of PD-L1 expression in patients with metastatic GEP-NET.

PD-L1 expression has been studied in many cancers [@B9]-[@B15]. Studies of breast cancer showed that the expression of PD-L1 was associated with poor prognosis features: large tumor size, high grade, negative hormone receptor status, positive HER2 status, and high proliferative rate [@B24]. The characteristics of indolent or aggressive GEP-NET were determined by tumor grade or differentiation [@B17], [@B25]. In general, tumor grade or differentiation has been based on the World Health Organization (WHO) classification. The 2010 WHO classification divides NETs into two main subgroups, tumor (NET) and carcinoma (NEC), according to Ki67 value and mitotic count. NET is defined as \<20% Ki67 and/or \<20/high power field (HPF) mitotic count, and is further sub-classified into Grade 1 (G1) (Ki67 ≤2 and/or mitosis ≤5) and Grade 2 (Ki67 3-20% and/or mitosis 5-20/HPF) [@B26]. All NETs with Ki67 \>20% and/or mitosis \>20/HPF are Grade 3 tumors (NECs), which includes small-cell or large-cell carcinoma. Thus, grade 3 GEP-NETs have more proliferative and aggressive clinicopathologic features. Our finding that expression of PD-L1 was related to a more proliferative and aggressive grade 3 type of GEP-NET was consistent with previous studies [@B24], [@B27], [@B28]. This correlation between the expression of PD-L1 and more proliferative tumor type might be caused by the higher aberration rate of hyperproliferative tumor cells, which is responsible for higher immunogenicity due to the rapid appearance of neoantigens.

Anti-PD-L1 therapies are under the spotlight in oncology as next-generation anticancer agents. Herbst et al. showed that anti-PD-L1 therapy (MPDL3280A) was safe and active in several cancer types, including non-small cell lung cancer, melanoma, renal cell carcinoma, and other solid tumors [@B8]. Powles et al. also reported that MPDL3280A was a new therapeutic option for patients with bladder cancer. In these two studies, tumor expression of PD-L1 was associated with a higher response to anti-PD-L1 therapy [@B22]. In our study, 7 of 32 (21.9%) patients had expression of PD-L1 in tumor tissues. In particular, in the subgroup of grade 3 GEP-NETs 7 of 17 (41.2%) patients had tumor expression of PD-L1. There are limited therapeutic options for grade 3 GEP-NET (NEC). The high proportion of PD-L1 expression in grade 3 GEP-NETs suggests that anti-PD-L1 therapy may be a useful new therapeutic modality for this subgroup of GEP-NETs. However, although overexpression of PD-L1 might serve as a predictor of tumors that have successfully evaded an immune response, nivolumab, anti-PD1 antibody, could alleviate inhibitory T-cell signaling independently of tumoral PD-L1 expression [@B29]. In view of similar observations of clinical activity of anti-PD1/PD-L1 therapeutic antibodies in PD-L1 negative patients [@B30]-[@B32], PD-L1 expression might not be necessary for achieving objective response with these agents.

Our study was a retrospective analysis with a small sample size. In addition, there was a lack of standardization of PD-L1 IHC, notably in terms of specificity and reproducibility of available antibodies and the definition of optimal positivity cut-off and interpretative subjectivity. Nevertheless, this analysis identified clinicopathologic characteristics related to expression of PD-L1 in metastatic GEP-NETs and evaluated the predictive and prognostic values of PD-L1 in GEP-NETs for survival. These data may provide useful information and background for future research for immunotherapy for GEP-NET.
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###### 

Baseline characteristics in 32 gastroenteropancreatic neuroendocrine tumors (GEP-NETs) patients.

  Variables                            n             \%
  ------------------------------------ ------------- -------
  Gender                                             
  Male                                 18            56.3
  Female                               14            43.7
  Age, years                                         
  Median, range                        60, (35-88)   
  Primary tumor site                                 
  Stomach                              1             3.1
  Duodenum                             2             6.2
  Gall Bladder                         6             18.8
  Biliary                              1             3.1
  Pancreas                             14            43.8
  Rectum                               8             25.0
  WHO classification                                 
  Grade II neuroendocrine tumor        15            46.9
  Grade III neuroendocrine carcinoma   17            53.1
  Liver metastasis                                   
  Yes                                  32            100.0
  Number of metastatic sites                         
  1                                    11            34.4
  2 ≤                                  21            65.6
  First line treatment                               
  Only supportive care                 7             21.9
  Systemic treatment                   25            78.1

###### 

The difference of PDL1 expression by immunohistochemistry (IHC) according to clinical characteristics.

  \(A\) Gender (Male vs Female), p=1.000                                               
  -------------------------------------------------------------- ---------- ---------- -------
  PDL1 IHC                                                                             
  Gender                                                         Positive   Negative   Total
  Male                                                           4          14         18
  Female                                                         3          11         14
  Total                                                          7          25         32
  **(B) Primary site (Foregut vs Midgut vs Hindgut), p=1.000**                         
  PDL1 IHC                                                                             
  Primary                                                        Positive   Negative   Total
  Foregut                                                        5          19         24
  Hindgut                                                        2          6          8
  Total                                                          7          25         32
  **(C) WHO classification (Grade II vs Grade III), p=0.008**                          
  PDL1 IHC                                                                             
  WHO                                                            Positive   Negative   Total
  Grade II                                                       0          15         15
  Grade III                                                      7          10         17
  Total                                                          7          25         32
  **(D) Number of metastatic sites (1 vs 2≤), p=0.719**                                
  PDL1 IHC                                                                             
  Metastatic sites                                               Positive   Negative   Total
  1                                                              2          9          11
  2≤                                                             5          16         21
  Total                                                          7          25         32

###### 

The difference of response for 1^st^ line treatment according to PD-L1 expression by immunohistochemistry (IHC) p=0.028, p=1.000.

                          PD-L positive   PD-L1 negative
  ----------------------- --------------- ----------------
  1st line chemotherapy   N=4             N=17
  Partial response        3               2
  Stable disease          0               9
  Progressive disease     1               5
  Response rate           75.0%           11.8%
  Disease control rate    75.0%           64.7%
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